Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX - Free Report) from a hold rating to a sell rating in a research note published on Monday.

Several other research firms also recently weighed in on IMUX. D. Boral Capital reiterated a "buy" rating and set a $17.00 target price on shares of Immunic in a research report on Tuesday, January 7th. HC Wainwright assumed coverage on shares of Immunic in a report on Monday, November 25th. They set a "buy" rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $12.67.

Immunic Trading Down 0.0 %

Shares of NASDAQ IMUX traded down $0.00 during midday trading on Monday, hitting $0.95. The company's stock had a trading volume of 281,416 shares, compared to its average volume of 943,270. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11. The firm has a market cap of $85.58 million, a P/E ratio of -0.77 and a beta of 1.87. The business's 50 day moving average is $1.05 and its two-hundred day moving average is $1.27.

Institutional Investors Weigh In On Immunic

Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Immunic in the 3rd quarter worth approximately $50,000. Jane Street Group LLC boosted its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after acquiring an additional 38,553 shares in the last quarter. HB Wealth Management LLC purchased a new position in shares of Immunic in the 4th quarter valued at $81,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after acquiring an additional 42,383 shares during the period. Finally, State Street Corp raised its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.